Imagen Biotech, Inc., a biopharmaceutical company focused on identifying and developing therapeutics for blinding diseases, has secured up to $40m in Series A financing.
Backers include SV Life Sciences, Novo Ventures, and Fidelity Biosciences.
The company intends to use the funds to pursue the identification and development of innovative treatments for blinding diseases including dry age-related macular degeneration (dry AMD).
The company was founded in the summer of 2011 by ophthalmologist Matthew Feinsod, MD, who will lead these efforts as Chief Medical Officer. Co-founders include David Guyer, MD, a partner at SV Life Sciences, who will serve as the Executive Chairman while Scott Cousins, MD, a Professor of Ophthalmology and Director of the Duke Center for Macular Diseases, who is CSO.